Overview

This is a prospective, multicentre, non-interventional, observational, real-world evidence (RWE) study designed to evaluate the effectiveness and safety of Immunoglobulin/Histamine Complex (IHC) in patients with Chronic Urticaria in India.

Eligibility

Inclusion Criteria:

1. Male or female patients aged ≥13 years.
2. Able and willing to provide written informed consent (or assent where applicable).
3. Diagnosed with chronic urticaria with UAS7 prior to enrollment already on first line of treatment for Chronic Urticaria
4. Prescribed Histoglob injections for the first time at the discretion of treating physician as part of routine car

Exclusion Criteria:

1. Known allergy or hypersensitivity to Histoglob or human immunoglobulin product.
2. Patients with acute allergic attack
3. Pregnant or lactating women.
4. History of malignancy or any condition requiring immunosuppressive therapy other than study indication.
5. Participation in any other clinical study.
6. Any other condition or circumstance that, in the opinion of the study physician, makes the patient unsuitable for study participation